Alpine Immune Sciences Inc (NASDAQ:ALPN)
| 10.55 BATS BZX Real-Time Price As of 12:32pm ET |  -0.18 / -1.68%Today’s Change | 2.05 Today|||52-Week Range 15.00 | +174.74% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $197.1M |
Company Description
Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company. The firm engages in the discovering of protein-based immunotherapies therapies targeting the immune synapse to treat cancer, autoimmune, and inflammatory disorders. It offers Immunotherapy, Immune Synapse, vIgD Platform Technology, and TIP Program. The company was founded in 2015 and is headquartered in Seattle, WA.
Contact Information
Alpine Immune Sciences, Inc. 188 East Blaine Street Seattle Washington 98102 |
Employees
Shareholders
| Individual stakeholders | 54.12% |
| Other institutional | 28.52% |
| Mutual fund holders | 1.51% |
Top Executives
| Mitchell H. Gold | Executive Chairman & Chief Executive Officer |
| Stanford L. Peng | President & Head-Research & Development |
| Thaedra Thullberry | Finance Director |
| James Paul Rickey | Chief Financial Officer & Senior Vice President |
| Kristine Swiderek | Senior Vice President-Research |
